Regeneron Pharmaceuticals and Telix Pharmaceuticals announced a joint venture to develop and commercialize next‑generation radiopharmaceutical therapies for solid tumors. The partnership combines Regeneron’s VelocImmune® antibody discovery platform with Telix’s radiopharmaceutical development and global manufacturing capabilities, creating a new modality within Regeneron’s oncology pipeline.
Under the agreement, Telix will receive an upfront cash payment of $40 million for access to Regeneron’s platform for four initial therapeutic programs. The parties will share development costs and profits on a 50/50 basis. Telix also retains the option to co‑promote certain products. If Telix opts out of the co‑funding model for a program, it is eligible for up to $535 million in development and commercial milestones, plus low double‑digit royalties on future net sales. The aggregate milestone value across all programs could reach $2.1 billion.
The collaboration expands Regeneron’s oncology portfolio by adding radiopharmaceuticals, a rapidly growing precision‑oncology segment. Telix’s expertise in radiopharmaceutical manufacturing and its existing portfolio—including Illuccix® and Gozellix®—provides the infrastructure needed to bring these agents to market quickly. Telix’s Q1 2026 results showed revenue up 24% year‑over‑year and 11% quarter‑over‑quarter, underscoring the company’s growth momentum.
Regeneron’s Q1 2026 financials will reflect a $102 million in‑process research and development charge, which is expected to reduce GAAP and non‑GAAP net income per diluted share by about $0.81. The charge is linked to the collaboration and other licensing agreements, illustrating the upfront investment Regeneron is making to expand its therapeutic toolbox.
"At Regeneron, we follow the science to determine the best therapeutic approach for each disease, continuously expanding our toolbox of treatment modalities – from monoclonal and bispecific antibodies to cell therapies and beyond. Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need," said John Lin, Senior Vice President of Oncology & Antibody Technology Research.
"Telix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron's antibody technologies and oncology portfolio," said Christian Behrenbruch, Managing Director and Group CEO of Telix. "Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD‑1 inhibitor is a global standard of care."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.